A population‐based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination1. Issue 1 (20th June 2012)

• Record Type: Journal Article
• Authors: Wheeler, Cosette M.; Hunt, William C.; Cuzick, Jack; Langsfeld, Erika; Pearse, Amanda; Montoya, George D.; Robertson, Michael; Shearman, Catherine A.; Castle, Philip E.; For The New Mexico HPV Pap Registry Steering Committee
• Is Part Of: International journal of cancer. Volume 132:Issue 1(2013:Jan. 01)
• Page Start: 198
• Page End: 207
• Publication Date: 2012-06-20
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.27608
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real‐world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population‐based measurement of HPV type‐specific prevalence employing an age‐ and cytology‐stratified sample of 47, 617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well‐validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid‐based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤20 years, 21–29 years or ≥30 years were 9.6, 6.5 and 1.8%, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high‐grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low‐grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (<italic>i.e.</italic>, type replacement).</p> </abstract>